NASDAQ: SRZN
Surrozen Inc Stock Forecast, Predictions & Price Target

Analyst price target for SRZN

Based on 1 analyst offering 12 month price targets for Surrozen Inc

Min Forecast
$40.00+58.67%
Avg Forecast
$40.00+58.67%
Max Forecast
$40.00+58.67%

Should I buy or sell SRZN stock?

Based on 1 analyst offering ratings for Surrozen Inc.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although SRZN's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates SRZN as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their SRZN stock forecasts and price targets.

SRZN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-02-19

1 of 1

Forecast return on equity

Is SRZN forecast to generate an efficient return?

Forecast return on assets

Is SRZN forecast to generate an efficient return on assets?

Company
-47.5%
Industry
32.08%
SRZN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SRZN earnings per share forecast

What is SRZN's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$4.52
Avg 2 year Forecast
-$3.88
Avg 3 year Forecast
-$5.52

SRZN revenue forecast

What is SRZN's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$1.3M-18.38%
Avg 2 year Forecast
$1.3M-18.38%
Avg 3 year Forecast
$0.0-100%
SRZN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

SRZN revenue growth forecast

How is SRZN forecast to perform vs Biotechnology companies and vs the US market?

Company
-45.35%
Industry
37.55%
Market
13.46%
SRZN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
SRZN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

SRZN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SRZN$25.21$40.00+58.67%Strong Buy
HUMA$1.16$13.67+1,078.19%Strong Buy
KROS$11.02$20.50+86.03%Buy
MDWD$16.58$36.00+117.13%Buy
CGEN$2.24$4.00+78.57%Buy

Surrozen Stock Forecast FAQ

Is Surrozen Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: SRZN) stock is to Strong Buy SRZN stock.

Out of 1 analyst, 1 (100%) are recommending SRZN as a Strong Buy, 0 (0%) are recommending SRZN as a Buy, 0 (0%) are recommending SRZN as a Hold, 0 (0%) are recommending SRZN as a Sell, and 0 (0%) are recommending SRZN as a Strong Sell.

If you're new to stock investing, here's how to buy Surrozen stock.

What is SRZN's earnings growth forecast for 2026-2028?

(NASDAQ: SRZN) Surrozen's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.33%.

Surrozen's earnings in 2026 is -$104,844,000.On average, 5 Wall Street analysts forecast SRZN's earnings for 2026 to be -$38,701,680, with the lowest SRZN earnings forecast at -$40,487,964, and the highest SRZN earnings forecast at -$33,029,971. On average, 5 Wall Street analysts forecast SRZN's earnings for 2027 to be -$33,222,828, with the lowest SRZN earnings forecast at -$41,243,964, and the highest SRZN earnings forecast at -$24,569,978.

In 2028, SRZN is forecast to generate -$47,298,815 in earnings, with the lowest earnings forecast at -$45,443,960 and the highest earnings forecast at -$48,689,957.

What is SRZN's revenue growth forecast for 2026-2028?

(NASDAQ: SRZN) Surrozen's forecast annual revenue growth rate of -45.35% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.55%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.46%.

Surrozen's revenue in 2026 is $1,638,000.On average, 5 Wall Street analysts forecast SRZN's revenue for 2026 to be $11,459,990, with the lowest SRZN revenue forecast at $0, and the highest SRZN revenue forecast at $35,391,397. On average, 5 Wall Street analysts forecast SRZN's revenue for 2027 to be $11,459,990, with the lowest SRZN revenue forecast at $0, and the highest SRZN revenue forecast at $35,391,397.

In 2028, SRZN is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is SRZN's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: SRZN) forecast ROA is -47.5%, which is lower than the forecast US Biotechnology industry average of 32.08%.

What is SRZN's Price Target?

According to 1 Wall Street analyst that have issued a 1 year SRZN price target, the average SRZN price target is $40.00, with the highest SRZN stock price forecast at $40.00 and the lowest SRZN stock price forecast at $40.00.

The Wall Street analyst predicted that Surrozen's share price could reach $40.00 by Feb 19, 2027. The average Surrozen stock price prediction forecasts a potential upside of 58.67% from the current SRZN share price of $25.21.

What is SRZN's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: SRZN) Surrozen's current Earnings Per Share (EPS) is -$22.34. On average, analysts forecast that SRZN's EPS will be -$4.52 for 2026, with the lowest EPS forecast at -$4.72, and the highest EPS forecast at -$3.85. On average, analysts forecast that SRZN's EPS will be -$3.88 for 2027, with the lowest EPS forecast at -$4.81, and the highest EPS forecast at -$2.87. In 2028, SRZN's EPS is forecast to hit -$5.52 (min: -$5.30, max: -$5.68).

What is SRZN's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: SRZN) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.